Hemophilia B

• EMA approval · 2026-08-27
  EMA Authorised: Hemgenix (Etranacogene dezaparvovec) — CSL Behring GmbH

  Authorised gene therapy Hemgenix (etranacogene dezaparvovec) for Hemophilia B with conditional approval by EMA.

• CLINICAL_TRIALS trial_result · 2026-08-14
  Clinical Trial Results: Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B [Phase 3]

  Phase 3 trial results for PF-06741086 in adults and adolescents with severe Hemophilia A or moderately to severely severe Hemophilia B; stud…

• CLINICAL_TRIALS trial_result · 2026-07-31
  Clinical Trial Results: Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B [Phase 1, Phase 2]

  Phase 1/2 dose-confirmation study of FLT180a in Hemophilia B was terminated; results were posted.

• CLINICAL_TRIALS trial_result · 2026-07-23
  Clinical Trial Update: Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy [Phase 3]

  Phase 3 trial update of rIX-FP in Chinese patients with Hemophilia B previously treated with FIX therapy; study completed.

• EMA approval · 2026-07-16
  EMA Authorised: Hympavzi (marstacimab) — Pfizer Europe MA EEIG

  EMA authorised Hympavzi (marstacimab) for hemophilia A and B, expanding treatment options for these conditions.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2026-07-14
  EMA Authorised: Hemgenix (Etranacogene dezaparvovec) — CSL Behring GmbH

  The EMA has authorised Hemgenix (etranacogene dezaparvovec) for Hemophilia B under conditional approval as an orphan medicine.

• EMA approval · 2026-07-06
  EMA Authorised: Alprolix (eftrenonacog alfa) — Swedish Orphan Biovitrum AB (publ)

  Authorised status for Alprolix (eftrenonacog alfa) by Swedish Orphan Biovitrum AB, approved for Hemophilia B.